This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Trial of Long-Acting Injectable Risperidone in the Treatment of Methamphetamine Dependence

This study has been completed.
Janssen, LP
Information provided by:
Seattle Institute for Biomedical and Clinical Research Identifier:
First received: January 27, 2006
Last updated: January 3, 2008
Last verified: January 2008

Objective of the Project.

-Methamphetamine (MA) use is growing to epidemic proportions and existing treatments for MA dependence demonstrate sub-optimal efficacy. Research implicates heavy use of MA as at least a contributing agent to a variety of neuropsychiatric impairments including psychosis, mood disturbance, anxiety, cognitive deficits, and motor dysfunction. Initial study by this investigator suggests that agents like risperidone may also be beneficial to MA dependent individuals by decreasing MA use and improving cognitive function in early abstinence. Long-acting injectable risperidone may prove more efficacious given its receptor binding characteristics and potential to increase medication adherence. The study objective is to determine the safety and efficacy of treating MA dependence and the associated cognitive and psychiatric symptomatology with long-acting injectable risperidone.

Condition Intervention Phase
Methamphetamine Dependence Drug: long-acting injectable risperidone Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Trial of Long-Acting Injectable Risperidone in the Treatment of Methamphetamine Dependence

Resource links provided by NLM:

Further study details as provided by Seattle Institute for Biomedical and Clinical Research:

Primary Outcome Measures:
  • Efficacy will be assessed by obtaining weekly self-report measures of MA and other substance use via the timeline follow-back interview corroborated with weekly urine toxicology specimens for substances of abuse including amphetamines.

Secondary Outcome Measures:
  • Secondary efficacy measures include:
  • changes in neuropsychological performance,
  • changes in psychiatric symptomatology,
  • by changes in addiction severity

Estimated Enrollment: 20
Study Start Date: January 2006
Study Completion Date: August 2007
Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Meets DSM-IV criteria for methamphetamine (MA) dependence during the past year with current MA use within the 30-days prior to study entry
  • Plans to remain in the Puget Sound area for the following 12 weeks
  • If female of child bearing potential, agreeable to using an adequate method of birth control
  • Age 18-65 years old
  • Willing and capable of providing informed consent
  • Presence of one or more of the following: stable address, telephone number, or alternative contact person

Exclusion Criteria:

  • Known sensitivity or allergy to risperidone
  • Current treatment with an antipsychotic agent
  • Current treatment with a mood stabilizer
  • Current treatment with a CYP 2D6 inhibitor (includes Amiodarone, Bupropion, Celecoxib, Cimetidine, Chlorpromazine, Clomipramine, Fluoxetine, Haloperidol, Methadone, Moclobemide, Paroxetine, Quinidine, Ritonavir, Sertraline, Terbinafine and Thioridazine)
  • Presence of tardive dyskinesia
  • A global item score >2 on the Barnes Akathisia Rating Scale.
  • A total score on the Simpson-Angus Scale > 0.3.
  • Albumin level <3.5g/dl.
  • Random serum glucose level >200mg/dl.
  • Transaminase levels > 5X ULN
  • Presence of one or more of the following medical conditions: diabetes mellitus or history of myocardial infarction.
  • A total score on the Brief Psychiatric Rating Scale >72.
  • Involvement with the legal system that could compromise study participation
  • Pregnancy or nursing
  • Receiving concurrent mental health treatment in addition to the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00284206

United States, Washington
VA Puget Sound Health Care System, Addictions Treatment Center
Seattle, Washington, United States, 98108
Sponsors and Collaborators
Seattle Institute for Biomedical and Clinical Research
Janssen, LP
Principal Investigator: Andrew J Saxon VA Puget Sound Health Care System, and University of Washington Dept. of Psychiatry and Behavioral Sciences
  More Information Identifier: NCT00284206     History of Changes
Other Study ID Numbers: RIS-NAP-4008
Study First Received: January 27, 2006
Last Updated: January 3, 2008

Keywords provided by Seattle Institute for Biomedical and Clinical Research:
methamphetamine, cognition, outpatient, risperidone

Additional relevant MeSH terms:
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents
Central Nervous System Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Dopamine Uptake Inhibitors processed this record on September 20, 2017